Amyris (AMRSQ) 10-Q 7 Oct 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Sep. 26, 2019
Document Information [Line Items]
Entity Registrant Name	AMYRIS, INC.
Entity Central Index Key	0001365916
Trading Symbol	amrs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		103,400,207
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents		$ 5,153	$ 45,353
Restricted cash		623	741
Accounts receivable, net		10,968	16,003
Accounts receivable - related party, net		1,334	1,349
Accounts receivable, unbilled - related party			8,021
Inventories		8,486	9,693
Deferred cost of products sold - related party		1,489	489
Prepaid expenses and other current assets		8,215	10,566
Total current assets		36,268	92,215
Property, plant and equipment, net		21,558	19,756
Accounts receivable, unbilled, noncurrent - related party	[1]	1,203	1,203
Deferred cost of products sold, noncurrent - related party		9,001	2,828
Restricted cash, noncurrent		960	960
Recoverable taxes from Brazilian government entities		2,964	3,005
Right-of-use assets under operating leases (Note 2)		27,645
Other assets		5,548	7,958
Total assets		105,147	127,925
Current liabilities:
Accounts payable		28,604	26,844
Accrued and other current liabilities		33,591	28,979
Lease liabilities (Note 2)		11,424
Contract liabilities		8,333	8,236
Debt, current portion (instrument measured at fair value $60,048 and $57,918, respectively)		129,393	124,010
Related party debt, current portion		24,359	23,667
Total current liabilities		235,704	211,736
Long-term debt, net of current portion		42,928	43,331
Related party debt, net of current portion		19,147	18,689
Lease liabilities, net of current portion (Note 2)		18,850
Derivative liabilities		3,798	42,796
Other noncurrent liabilities		16,920	23,192
Total liabilities		337,347	339,744
Commitments and contingencies (Note 8)
Mezzanine Equity		5,000	5,000
Stockholders’ deficit:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March 31, 2019 and December 31, 2018, and 14,656 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively
Common stock - $0.0001 par value, 250,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 77,210,681 and 76,564,829 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively		8	8
Additional paid-in capital		1,383,363	1,346,996
Accumulated other comprehensive loss		(42,379)	(43,343)
Accumulated deficit		(1,579,129)	(1,521,417)
Total Amyris, Inc. stockholders’ deficit		(238,137)	(217,756)
Noncontrolling interest		937	937
Total stockholders' deficit		(237,200)	(216,819)
Total liabilities, mezzanine equity and stockholders' deficit		$ 105,147	$ 127,925
[1]	As of March 31, 2019 and December 31, 2018, contract liabilities, noncurrent is presented in Other Noncurrent Liabilities in the consolidated balance sheets because of its insignificance.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts receivable, allowance	$ 126	$ 642
Accounts receivable, related party, allowance	12	0
Debt, current portion, fair value	$ 60,048	$ 57,918
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	14,656	14,656
Preferred stock, shares outstanding (in shares)	14,656	14,656
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	77,210,681	76,564,829
Common stock, shares outstanding (in shares)	77,210,681	76,564,829

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue:
Revenues	$ 14,374,000	$ 17,859,000
Cost and operating expenses:
Cost of products sold	17,707,000	5,315,000
Research and development	17,839,000	17,825,000
Sales, general and administrative	28,253,000	18,100,000
Total cost and operating expenses	63,799,000	41,240,000
Loss from operations	(49,425,000)	(23,381,000)
Other income (expense):
Loss on divestiture		(1,778,000)
Interest expense	(12,534,000)	(9,978,000)
Loss from change in fair value of derivative instruments	(2,039,000)	(58,357,000)
Loss from change in fair value of debt	(48,000)
Other income (expense), net	(115,000)	692,000
Total other income (expense), net	(16,818,000)	(69,421,000)
Loss before income taxes	(66,243,000)	(92,802,000)
Provision for income taxes
Net loss attributable to Amyris, Inc.	(66,243,000)	(92,802,000)
Less: losses allocated to participating securities	2,430,000	7,504,000
Net loss attributable to Amyris, Inc. common stockholders	$ (63,813,000)	$ (85,298,000)
Loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.82)	$ (1.67)
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares)	77,512,059	51,200,922
Product [Member]
Revenue:
Revenues	$ 11,884,000	$ 5,195,000
Licenses and Royalties [Member]
Revenue:
Revenues	118,000	7,955,000
Grants and Collaborations [Member]
Revenue:
Revenues	$ 2,372,000	$ 4,709,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues, related party	$ 18	$ 8,803
Product [Member]
Revenues, related party	2	151
Licenses and Royalties [Member]
Revenues, related party	(380)	7,918
Grants and Collaborations [Member]
Revenues, related party	$ 396	$ 734

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Comprehensive loss:
Net loss attributable to Amyris, Inc.	$ (66,243)	$ (92,802)
Foreign currency translation adjustment	964	(137)
Comprehensive loss attributable to Amyris, Inc.	$ (65,279)	$ (92,939)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Mezzanine Equity, Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	22,171	45,637,433
Balance at Dec. 31, 2017		$ 5	$ 1,114,546	$ (42,156)	$ (1,290,420)	$ 937	$ 5,000	$ (217,088)
Cumulative effect of change in accounting principle (Accounting Standards Update 2014-09 [Member]) at Dec. 31, 2017					(803)			(803)
Issuance of common stock upon exercise of warrants (in shares)		162,392
Issuance of common stock upon exercise of warrants			835					835
Issuance of common stock upon exercise of stock options (in shares)		7,004
Issuance of common stock upon exercise of stock options			81					81
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)		30,489
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock			(66)					(66)
Stock-based compensation			1,278					1,278
Foreign currency translation adjustment				(137)				(137)
Net loss					(92,802)			(92,802)
Issuance for private placement, net (in shares)		13,529
Issuance for private placement, net			92					92
Other			93					93
Balance (in shares) at Mar. 31, 2018	22,171	45,850,847
Balance at Mar. 31, 2018		$ 5	1,116,859	(42,293)	(1,384,025)	937	5,000	$ (308,517)
Balance (in shares) at Dec. 31, 2018	14,656	76,564,829						76,564,829
Balance at Dec. 31, 2018		$ 8	1,346,996	(43,343)	(1,521,417)	937	5,000	$ (216,819)
Cumulative effect of change in accounting principle (Accounting Standards Update 2017-11 [Member]) at Dec. 31, 2018			32,512		8,531			$ 41,043
Issuance of common stock upon exercise of warrants (in shares)		450,568						479,751
Issuance of common stock upon exercise of warrants			1					$ 1
Issuance of common stock upon exercise of stock options (in shares)		3,612						3,612
Issuance of common stock upon exercise of stock options			13					$ 13
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)		191,672
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock			(9)					(9)
Stock-based compensation			3,452					3,452
Fair value of bifurcated embedded conversion feature in connection with debt modification			398					398
Foreign currency translation adjustment				964				964
Net loss					(66,243)			(66,243)
Balance (in shares) at Mar. 31, 2019	14,656	77,210,681
Balance at Mar. 31, 2019		$ 8	$ 1,383,363	$ (42,379)	$ (1,579,129)	$ 937	$ 5,000	$ (237,200)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Operating activities
Net loss	$ (66,243,000)	$ (92,802,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	4,628,000	4,789,000
Stock-based compensation	3,452,000	1,278,000
Loss from change in fair value of debt	48,000		$ (2,082,000)
Loss from change in fair value of derivative liabilities	2,039,000	58,357,000
Amortization of right-of-use assets under operating leases	2,826,000
Depreciation and amortization	848,000	1,561,000
Write-down of property, plant and equipment	438,000
Loss on disposal of property, plant and equipment	1,000	1,035,000
(Gain) loss on foreign currency exchange rates	(108,000)	243,000
Changes in assets and liabilities:
Accounts receivable	5,048,000	74,000
Accounts receivable, unbilled - related party	8,021,000	93,000
Inventories	1,196,000	420,000
Deferred cost of products sold	(7,173,000)
Prepaid expenses and other assets	1,766,000	6,747,000
Accounts payable	1,834,000	(108,000)
Accrued and other liabilities	6,245,000	(11,120,000)
Lease liabilities	(4,036,000)
Contract liabilities	108,000	4,264,000
Net cash used in operating activities	(36,980,000)	(25,169,000)
Investing activities
Purchases of property, plant and equipment	(3,046,000)	(1,584,000)
Net cash used in investing activities	(3,046,000)	(1,584,000)
Financing activities
Proceeds from issuance of debt, net of issuance costs	484,000
Proceeds from exercises of common stock options	13,000	81,000
Proceeds from exercises of warrants	1,000	133,000
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units	(9,000)	(66,000)
Principal payments on financing leases	(134,000)	(400,000)
Principal payments on debt	(577,000)	(6,534,000)
Proceeds from issuance of common stock in private placements, net of issuance costs		92,000
Net cash used in financing activities	(222,000)	(6,694,000)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(70,000)	(68,000)
Net decrease in cash, cash equivalents and restricted cash	(40,318,000)	(33,515,000)
Cash, cash equivalents and restricted cash at beginning of period	47,054,000	61,012,000	61,012,000
Cash, cash equivalents and restricted cash at end of the period	6,736,000	27,497,000	47,054,000
Cash and cash equivalents	5,153,000	24,084,000	45,353,000
Restricted cash, current	623,000	2,454,000	741,000
Restricted cash, noncurrent	960,000	959,000	$ 960,000
Supplemental disclosures of cash flow information:
Cash paid for interest	3,099,000	1,815,000
Supplemental disclosures of non-cash investing and financing activities:
Right-of-use assets under operating leases recorded upon adoption of ASC 842 (Note 2)	29,713,000
Lease liabilities recorded upon adoption of ASC 842 (Note 2)	33,552,000
Cumulative effect of change in accounting principle for ASU 2017-11 (Note 2)	41,043,000
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable	605,000	264,000
Acquisition of right-of-use assets under operating leases	758,000
Right-of-use assets amortization capitalized into inventory	1,800,000
Accrued interest added to debt principal	448,000	1,211,000
Fair value of warrants recorded as debt discount in connection with debt modification	398,000
Financing of equipment		$ 91,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Amyris, Inc. (Amyris or the Company) is a leading industrial biotechnology company that applies its technology platform to engineer, manufacture and sell high performance, natural, sustainably-sourced products into the Health & Wellness, Clean Beauty, and Flavor & Fragrance markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company has successfully used its technology to develop and produce several distinct molecules at commercial volumes. The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10 December 31, 2018 2018 10 December 31, 2018 10 10 X. not not Going Concern The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 March 31, 2019, $199.4 $119.5 December 31, 2018 $1.6 As of March 31, 2019, $13.5 $215.8 $153.8 March 31, 2019, 12, March 31, 2020 $179.8 $23.5 Cash and cash equivalents of $5.2 March 31, 2019 not March 31, 2020. one not twelve March 31, 2020 December 31, 2018, may may not On September 16, 2019, $63.6 The Company does not not no no not not Significant Accounting Policies Note 1, 2018 10 no three March 31, 2019, January 1, 2019: • 842 842 Leases; • 2017 11, Earnings Per Share (Topic 260 480 815 Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company generally does not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 2018 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely amount method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Contract liability arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not For descriptions of the Company's other significant accounting policies, see the 2018 10 Accounting Standards or Updates Recently Adopted In the three March 31, 2019, Leases February 2016, No. 2016 02, Leases (Topic 842 July 2018, 2018 11, Leases (Topic 842 842 The Company adopted this standard on January 1, 2019 1 2 3 not not not not not 12 not The adoption of this standard had the effect of increasing assets and liabilities on the condensed consolidated balance sheet by $25.7 not 1 2 Upon adoption, the Company recognized operating lease liabilities of $33.6 $29.7 Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019, 2017 11 $32.5 $8.5 $41.0 Recent Accounting Standards or Updates Not Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Collaborative Revenue Arrangements November 2018, 2018 18, Clarifying the Interaction between Topic 808 606 606, two first 2020 not Credit Losses June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 2016 13 first 2020. not Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may

Note 2 - Balance Sheet Details

Note 2 - Balance Sheet Details	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	2. Inventories (In thousands) March 31, 2019 December 31, 2018 Raw materials $ 2,451 $ 3,901 Work-in-process 238 539 Finished goods 5,797 5,253 Inventories $ 8,486 $ 9,693 Deferred cost of products sold - related party (In thousands) March 31, 2019 December 31, 2018 Deferred cost of products sold - related party $ 1,489 $ 489 Deferred cost of products sold, noncurrent - related party 9,001 2,828 Total $ 10,490 $ 3,317 In November 2018, 1 2022. 10, 8 2018 10 November 2018 $24.4 $3.3 December 31, 2018. three March 31, 2019, $7.3 $13.8 five December 2018, March 31, 2019. Prepaid expenses and other current assets (In thousands) March 31, 2019 December 31, 2018 Prepayments, advances and deposits $ 3,310 $ 5,644 Recoverable taxes from Brazilian government entities 956 631 Other 3,949 4,291 Total prepaid expenses and other current assets $ 8,215 $ 10,566 Property, Plant and Equipment, Net (In thousands) March 31, 2019 December 31, 2018 Machinery and equipment $ 45,874 $ 43,713 Leasehold improvements 39,951 39,922 Computers and software 10,138 9,987 Furniture and office equipment, vehicles and land 3,279 3,016 Construction in progress 1,460 1,749 Total property, plant and equipment, gross 100,702 98,387 Less: accumulated depreciation and amortization (79,144 ) (78,631 ) Property, plant and equipment, net $ 21,558 $ 19,756 During the three March 31, 2019 2018, $0.2 $0.8 Depreciation and amortization expense, including amortization of assets under financing leases, was $0.8 $1.6 three March 31, 2019 2018, Leases Operating Leases The Company has entered into operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 5 one 1 5 March 31, 2019 March 31, 2019 $29.7 $33.6 January 1, 2019. January 1, 2019 March 31, 2019, $27.6 $29.7 three March 31, 2019, $2.8 $1.8 Because the rate implicit in each lease is not may Information related to the Company's right-of-use assets and related lease liabilities were as follows: Amounts in thousands Three Months Ended March 31, 2019 Cash paid for operating lease liabilities $ 5,305 Right-of-use assets obtained in exchange for new operating lease obligations (1) $ 30,472 Weighted-average remaining lease term (in years) 2.7 Weighted-average discount rate 18.0 % ( 1 $29.7 January 1, 2019 $0.8 first 2019. Financing Leases The Company has entered into financing leases primarily for laboratory and computer equipment. Assets purchased under financing leases are included in "Property, plant and equipment, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Property, plant and equipment, net included $5.3 $5.0 March 31, 2019 December 31, 2018, $2.5 $2.3 March 31, 2019 December 31, 2018, Maturities of Financing and Operating Leases Maturities of lease liabilities as of March 31, 2019 Years ending December 31: Financing Leases Operating Total Leases 2019 (remaining nine months) $ 368 $ 12,755 $ 13,123 2020 199 9,109 9,308 2021 1 7,226 7,227 2022 — 7,398 7,398 2023 — 3,034 3,034 Thereafter — — — Total lease payments 568 39,522 40,090 Less: amount representing interest (23 ) (9,793 ) (9,816 ) Total lease liability $ 545 $ 29,729 $ 30,274 Current lease liability $ 452 $ 10,972 $ 11,424 Noncurrent lease liability 93 18,757 18,850 Total lease liability $ 545 $ 29,729 $ 30,274 Other Assets (In thousands) March 31, 2019 December 31, 2018 Contingent consideration $ 4,286 $ 4,286 Deposits 145 2,465 Other 1,117 1,207 Other assets $ 5,548 $ 7,958 Accrued and Other Current Liabilities (In thousands) March 31, 2019 December 31, 2018 DSM manufacturing capacity fee $ 7,250 $ — Contract termination fees 5,337 6,247 Accrued interest 7,094 3,853 Payroll and related expenses 5,285 9,220 Asset retirement obligation 3,111 3,063 Tax-related liabilities 2,589 2,139 Professional services 1,871 1,173 Other 1,054 3,284 Total accrued and other current liabilities $ 33,591 $ 28,979 Other noncurrent liabilities (In thousands) March 31, 2019 December 31, 2018 Contract termination fees, net of current portion $ 8,207 $ 7,715 Liability for unrecognized tax benefit 6,582 6,582 Contract liability, net of current portion (Note 9) 1,449 1,587 Deferred rent, net of current portion (1) — 6,440 Other 682 868 Total other noncurrent liabilities $ 16,920 $ 23,192 ( 1 December 31, 2018 January 1, 2019 842,

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	3. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following tables summarize assets and liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy: (In thousands) March 31, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities 6% Convertible Notes Due 2021 $ — $ — $ 60,048 $ 60,048 $ — $ — $ 57,918 $ 57,918 Freestanding derivative instruments in connection with the issuance of equity instruments — — 3,798 3,798 — — 42,796 42,796 Total liabilities measured and recorded at fair value $ — $ — $ 63,846 $ 63,846 $ — $ — $ 100,714 $ 100,714 There were no 6% 2021 The Company issued $60.0 6% 2021 December 10, 2018 March 31, 2019, $60.0 $60.0 23.8% 45% 50% 50% 5% 4, three March 31, 2019, $2.1 6% 2021, In thousands Fair value at December 31, 2018 $ 57,918 Change in fair value 2,130 Fair value at March 31, 2019 $ 60,048 Derivative Liabilities Recognized in Connection with the Issuance of Debt and Equity Instruments The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt and equity instruments, measured at fair value using significant unobservable inputs (Level 3 (In thousands) Equity-related Derivative Liability Debt-related Derivative Liability Total Derivative Liability Balance at December 31, 2018 $ 41,272 $ 1,524 $ 42,796 Derecognition upon adoption of ASU 2017-11 (39,513 ) (1,524 ) (41,037 ) Change in fair value of derivative liabilities 2,039 — 2,039 Balance at March 31, 2019 $ 3,798 $ — $ 3,798 As of March 31, 2019, November 2018 10, 8 2018 10 Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes are recorded at carrying value (except for the 6% 2021, 2 3 March 31, 2019, 6% $155.8 March 31, 2019 $155.8 third

Note 4 - Debt

Note 4 - Debt	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	4. Net carrying amounts of debt are as follows: March 31, 2019 December 31, 2018 (In thousands) Principal Unamortized Debt (Discount) Premium Change in Fair Value Net Balance Principal Unamortized Debt (Discount) Premium Change in Fair Value Net Balance Convertible notes payable 6% convertible notes due 2021 $ 60,000 $ — $ 48 $ 60,048 $ 60,000 $ — $ (2,082 ) $ 57,918 2015 Rule 144A convertible notes 37,887 (358 ) — 37,529 37,887 (2,413 ) — 35,474 2014 Rule 144A convertible notes 24,004 (289 ) — 23,715 24,004 (867 ) — 23,137 August 2013 financing convertible note 4,863 (596 ) — 4,267 4,415 (70 ) — 4,345 126,754 (1,243 ) 48 125,559 126,306 (3,350 ) (2,082 ) 120,874 Related party convertible notes payable 2014 Rule 144A convertible notes 24,705 (346 ) — 24,359 24,705 (1,038 ) — 23,667 Loans payable and credit facilities GACP secured term loan facility 36,000 (1,208 ) — 34,792 36,000 (1,349 ) — 34,651 Ginkgo note 12,000 (3,832 ) — 8,168 12,000 (4,047 ) — 7,953 Other loans payable 4,813 (1,011 ) — 3,802 4,910 (1,047 ) — 3,863 52,813 (6,051 ) — 46,762 52,910 (6,443 ) — 46,467 Related party loans payable DSM note 25,000 (5,853 ) — 19,147 25,000 (6,311 ) — 18,689 Total debt $ 229,272 $ (13,493 ) $ 48 215,827 $ 228,921 $ (17,142 ) $ (2,082 ) 209,697 Less: current portion (153,752 ) (147,677 ) Long-term debt, net of current portion $ 62,075 $ 62,020 The 6% 2021 March 31, 2019 December 31, 2018 March 31, 2019 March 31, 2019 December 31, 2018 12, On January 14, 2019, August 2013 January 15, 2019 July 15, 2019 July 15, 2019, $0.6 July 15, 2019, October 13, 2019 1.75% July 16, 2019 12, Future Minimum Payments Future minimum payments under the Company's debt agreements as of March 31, 2019 (In thousands) Convertible Loans Related Related Total 2019 (remaining nine months) $ 139,303 $ 9,689 $ 25,618 $ 1,875 $ 176,485 2020 — 10,113 — 2,500 12,613 2021 — 34,776 — 28,146 62,922 2022 — 13,450 — — 13,450 2023 — 399 — — 399 Thereafter — 2,268 — — 2,268 Total future minimum payments 139,303 70,695 25,618 32,521 268,137 Less: amount representing interest (12,303 ) (17,883 ) (913 ) (7,521 ) (38,620 ) Less: future conversion of accrued interest to principal (245 ) — — — (245 ) Present value of minimum debt payments 126,755 52,812 24,705 25,000 229,272 Less: current portion of debt principal (126,755 ) (4,513 ) (24,705 ) — (155,973 ) Noncurrent portion of debt principal $ — $ 48,299 $ — $ 25,000 $ 73,299

Note 5 - Mezzanine Equity

Note 5 - Mezzanine Equity	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Mezzanine Equity Disclosure [Text Block]	5. Mezzanine equity is comprised of the following: (In thousands) March 31, 2019 December 31, 2018 Contingently redeemable common stock $ 5,000 $ 5,000 Mezzanine equity at March 31, 2019 December 31, 2018 May 10, 2016 not third $17.10 10%. As of March 31, 2019, $0.6

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. Warrants In connection with various debt and equity transactions (see Note 5, 7, 8 2018 10 three March 31, 2019: Transaction Number Outstanding as of December 31, 2018 Additional Warrants Issued Exercises Number Outstanding as of March 31, 2019 August 2018 warrant exercise agreements 12,097,164 — — 12,097,164 May 2017 cash and dilution warrants 6,292,798 — — 6,292,798 August 2017 cash and dilution warrants 3,968,116 — — 3,968,116 April 2018 warrant exercise agreements 3,616,174 — — 3,616,174 July 2015 related party debt exchange 663,228 — (471,204 ) 192,024 February 2016 related party private placement 171,429 — — 171,429 July 2015 private placement 81,197 — (8,547 ) 72,650 Other 1,406 — — 1,406 26,891,512 — (479,751 ) 26,411,761 For the three March 31, 2019, 479,751 $0.01 no 450,568

Note 7 - Loss Per Share

Note 7 - Loss Per Share	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	7. For the three March 31, 2019 March 31, 2018, The Company follows the two two two The following table presents the calculation of basic and diluted loss per share: Three Months Ended March 31, (In thousands, except shares and per share amounts) 2019 2018 Numerator: Net loss attributable to Amyris, Inc. $ (66,243 ) $ (92,802 ) Less: losses allocated to participating securities 2,430 7,504 Net loss attributable to Amyris, Inc. common stockholders $ (63,813 ) $ (85,298 ) Denominator: Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted 77,512,059 51,200,922 Loss per share attributable to common stockholders, basic and diluted $ (0.82 ) $ (1.67 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive: Three Months Ended March 31, 2019 2018 Period-end stock options to purchase common stock 5,427,384 1,365,447 Convertible promissory notes (1) 12,699,607 8,347,364 Period-end common stock warrants 26,411,761 29,759,452 Period-end restricted stock units 5,493,579 706,697 Period-end preferred stock 2,955,732 4,504,212 Total potentially dilutive securities excluded from computation of diluted loss per share 52,988,063 44,683,172 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Contingencies Disclosure [Text Block]	8. Contingencies The Company has levied indirect taxes on sugarcane-based biodiesel sales that took place several years ago by Amyris Brasil Ltda. (see Note 12, 8 2018 10 On April 3, 2019, March 15, 2018 March 19, 2019. June 21, 2019 October 1, 2019, two No. 4:19 03621 No. 4:19 06230 not The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not not

Note 9 - Revenue Recognition an

Note 9 - Revenue Recognition and Contract Assets and Liabilities	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	9. Disaggregation of Revenue The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer: Three Months Ended March 31, (In thousands) 2019 2018 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 7,073 $ — $ 493 $ 7,566 $ 1,962 $ — $ 1,209 $ 3,171 Europe 2,854 118 1,629 4,601 2,434 7,955 3,500 13,889 Asia 1,718 — 250 1,968 678 — — 678 South America 220 — — 220 21 — — 21 Other 19 — — 19 100 — — 100 $ 11,884 $ 118 $ 2,372 $ 14,374 $ 5,195 $ 7,955 $ 4,709 $ 17,859 Significant Revenue Agreements During the Three Months Ended March 31, 2019 In connection with significant revenue agreements, the Company recognized the following revenues for the three March 31, 2019 2018 : Three Months Ended March 31, (In thousands) 2019 2018 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total Firmenich $ 1,891 $ 498 $ 728 $ 3,117 $ 207 $ 37 $ 1,267 $ 1,511 Givaudan 1,575 — — 1,575 1,076 — 1,500 2,576 American Sugar Refining 1,494 — — 1,494 — — — — DSM - related party 2 (380 ) 396 18 — 7,918 734 8,652 Subtotal revenue from significant revenue agreements 4,962 118 1,124 6,204 1,283 7,955 3,501 12,739 Revenue from all other customers 6,922 — 1,248 8,170 3,912 — 1,208 5,120 Total revenue from all customers $ 11,884 $ 118 $ 2,372 $ 14,374 $ 5,195 $ 7,955 $ 4,709 $ 17,859 Contract Assets and Liabilities When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade accounts receivable are recorded at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company for sale of goods or the performance of services. Contract Balances The following table provides information about accounts receivable and contract liabilities from contracts with customers: (In thousands) March 31, 2019 December 31, 2018 Accounts receivable, net $ 10,968 $ 16,003 Accounts receivable - related party, net $ 1,334 $ 1,349 Accounts receivable, unbilled - related party $ — $ 8,021 Accounts receivable, unbilled, noncurrent - related party $ 1,203 $ 1,203 Contract liabilities $ 8,333 $ 8,236 Contract liabilities, noncurrent (1) $ 1,449 $ 1,587 ( 1 March 31, 2019 December 31, 2018, Unbilled receivables at the end of the period relate to the Company’s right to consideration from DSM for performance fees. The Company’s right to cash receipt for these minimum royalty amounts occurs on or before December 31, 2019. December 31, 2018 March 31, 2019, $8.0 $8.0 December 31, 2019 $0.6 $7.4 $0.4 $0.2 Remaining Performance Obligations The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2019. (In thousands) As of March 31, 2019 Remaining 2019 $ 23,920 2020 38,508 2021 31,172 2022 and thereafter — Total from all customers $ 93,600 In accordance with the disclosure provisions of ASC 606, one $17.6

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10. Related Party Debt See Note 4, March 31, 2019 December 31, 2018. Related Party Accounts Receivable and Unbilled Receivables Related party accounts receivable and unbilled receivables as of March 31, 2019 December 31, 2018 (In thousands) March 31, 2019 December 31, 2018 Accounts receivable: DSM $ 1,334 $ 1,071 Novvi — 188 Total — 90 $ 1,334 $ 1,349 Accounts receivable, unbilled, current: DSM $ — $ 8,021 Accounts receivable, unbilled, noncurrent: DSM $ 1,203 $ 1,203 Related Party Joint Ventures The Company holds a 50%

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	11. The Company’s stock option activity and related information for the three March 31, 2019 Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2018 5,390,270 $ 11.55 8.5 $ 29 Granted 104,452 $ 4.73 Exercised (3,612 ) $ 3.68 Forfeited or expired (63,726 ) $ 14.27 Outstanding - March 31, 2019 5,427,384 $ 11.39 8.3 $ — Vested or expected to vest after March 31, 2019 4,874,155 $ 12.10 8.3 $ — Exercisable at March 31, 2019 977,466 $ 39.20 5.8 $ — The Company’s restricted stock units (RSUs) activity and related information for the three March 31, 2019 Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2018 5,294,803 $ 5.50 1.7 Awarded 493,790 $ 4.65 RSUs released (192,795 ) $ 6.55 RSUs forfeited (102,219 ) $ 5.61 Outstanding - March 31, 2019 5,493,579 $ 5.38 1.5 Vested or expected to vest after March 31, 2019 5,153,107 $ 5.39 1.5 Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three March 31, 2019 2018 Three Months Ended March 31, (In thousands) 2019 2018 Research and development $ 663 $ 363 Sales, general and administrative 2,789 915 Total stock-based compensation expense $ 3,452 $ 1,278 As of March 31, 2019, $31.1 3.0 Evergreen Shares for 2010 2010 In February 2019, 2010 2010 3,828,241 5.0% 76,564,829 December 31, 2018. January 1, 2019. 383,824 0.5% 76,564,829 December 31, 2018. January 1, 2019.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	12. Cannabinoid Agreement On May 2, 2019, March 18, 2019 $300 $300 20 third 2014 144A 2015 144A 4, May 2, 2019, 4, LSA Amendments, Assignment and Waivers On April 4, 2019, 4, December 31, 2018, July 1, 2021, ( $15 On April 4, 2019, December 31, 2018 April 8, 2019, $0.8 On April 15, 2019, five $2.5 April 16, 2019. On August 14, 2019, No. 5 July 1, 2021 July 1, 2022, ( x 4.75% 9% 12% December 16, 2019, ( December 16, 2019, ( April 8, 2019, June 11, 2019, July 10, 2019 July 26, 2019 ( $32.5 $71.0 August 14, 2019 1,438,829 $2.87 two may not 19.99% 2019 Foris Credit Agreements On April 8, 2019, $8.0 April April 8, 2019 $8.0 April April October 14, 2019. April April no $1.0 April April April $0.5 April July 15, 2019. April 4, 12, On June 11, 2019, $8.5 June 11, 2019 $8.5 June June 12.5% June 11, 2019, June August 28, 2019; May 2017 August 2017 6, June On July 10, 2019, $16.0 July $8.0 July 10, 2019 $8.0 July 26, 2019 $8.0 July July 12.5% July December 31, 2019. July August 17, 2018 ( 6, $7.52 $2.87 The Company may April April June July 100% June July On August 14, 2019, April June July On August 28, 2019, $19.0 August August 28, 2019 $19.0 August August 12% August 28, 2019, March 31, June 30, September 30 December 31, December 31, 2019, January 1, 2023. may August 100% August 28, 2019 August April 26, 2019 $5.12 $3.90 May 14, 2019 $4.56 $3.90 6, In connection with the entry into the August August 14, 2019 4,871,795 $3.90 two 4 2 1933, not six not may not 19.99% 2019 Private Placements On April 16, 2019, 6,732,369 $2.87 5,424,804 $2.87 two 4 2 $20.0 On April 26, 2019, 2,832,440 $5.12 3,983,230 $5.12 two 2,043,781 $4.02 1,635,025 $5.02 two 4 2 $23.2 August 28, 2019, August April 26, 2019 $5.12 $3.90 On April 29, 2019, 913,529 $4.76 1,212,787 $4.76 two 323,382 $4.02 258,704 $5.02 two 4 2 $5.8 On May 3, 2019, 1,243,781 $4.02 995,024 $5.02 two 4 2 $5 The exercise price of the warrants issued in the foregoing private placements is subject to standard adjustments but does not six not not not 19.99% DSM Agreements On April 16, 2019, 9, $57.0 $29.1 $27.9 2015 144A 4, In addition, on April 16, 2019 9, December 2017 13, 8 2018 10 2021, no On September 17, 2019, “2019 $8.0 $3.0 $3.0 $2.0 September 17, 2019, first $3.0 2019 $3.0 September 19, 2019, second $3.0 2019 $3.0 September 23, 2019, $2.0 2019 $1.5 $2.0 2019 August 7, 2022, ( 12.5% January 1, April 1, July 1 October 1, January 1, 2020, first may 2019 100% 2019 May 11, 2017 August 7, 2017 ( 7, $50.0 one June 30, 2020. Raizen Joint Venture Agreement On May 10, 2019, not December 31, 2019, may not Upon the closing of the joint venture, each party will make an initial capital contribution to the joint venture of 2,500,000 R$2,500,000 50% 50% 60 U.S.$9,000,000 U.S.$3,000,000. six 10 After the formation of the joint venture, the parties will not not third seventh 2015 2014 144A On April 16, 2019, $37.9 2015 144A On May 10, 2019, $13.5 2014 144A 4, May 15, 2019, 3,479,008 1,391,603 $5.02 two 3 9 On May 14, 2019, $5.0 2014 144A May 15, 2019, 1,122,460 352,638 $4.56 two 3 9 August 28, 2019, August May 14, 2019 $4.56 $3.90 On May 15, 2019, $10.0 2014 144A 2,500,000 3 9 On May 15, 2019, $9.7 2014 144A June 14, 2019, 3 9 June 14, 2019, June 14, 2019 July 18, 2019. July 18, 2019, July 18, 2019 August 28, 2019 10.50% July 18, 2019. The exercise price of the warrants issued in the foregoing exchanges is subject to standard adjustments but does not six not 2019 may not 4.99% 6% 2021 On May 15, 2019 June 24, 2019, $53.3 $4.7 6% 2021 4, 6% 2021, 2,000,000 181,818 $5.12 two 3 9 6% 2021 July 22, 2019, July 22, 2019 July 29, 2019, 125% not six not may not may not 4.99% On July 24, 2019, $53.3 6% 2021 2,000,000 May 15, 2019, $68.3 2,000,000 $2.87 two May 15, 2019 ( 3 9 May 15, 2019, $68.3 25% July 1, 2019 $6.4 not 18% July 22, 2019 September 16, 2019, ( first October 1, 2019, ( $3.2 August 2, 2019 August 22, 2019, September 16, 2019, 8 September 16, 2019, $2.87 On July 26, 2019, one 6% 2021, $4.7 June 24, 2019, 125% July 30, 2019 August 30, 2019. August 30, 2019. On September 16, 2019, $63.6 The Company does not not no no not not Exchange of August 2013 On July 8, 2019, August 2013 4, 1,767,632 1,080,000 3 9 not six not may not 4.99% Nikko Loan Agreement On July 29, 2019, $5.0 $3.0 $2.0 10, July 30, 2019, first $3.0 $2.8 $0.2 August 8, 2019, $2.0 $1.9 $0.1 December 18, 2020, ( 5% first 12.8% Aprinnova Working Capital Loan Effective July 31, 2019, 5, 2018 10 August 1, 2019 August 1, 2020. Naxyris Loan and Security Agreement On August 14, 2019, $10,435,000 August 14, 2019. Loans under the Naxyris Loan Facility have a maturity date of July 1, 2022 12% 25 August 14, 2019 December 1, 2019 December 15, 2019. The obligations of the Company under the Naxyris Loan Facility are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris Ventures subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement (as defined above). Mandatory prepayments of the outstanding amounts under the Naxyris Loan Facility will be required upon the occurrence of certain events, including asset sales, a change in control, and the incurrence of additional indebtedness, subject to certain exceptions and reinvestment rights. Outstanding amounts under the Naxyris Loan Facility must also be prepaid to the extent that the borrowing base exceeds the outstanding principal amount of the loans under the Naxyris Loan Facility. In addition, the Company may one 6% three not The affirmative and negative covenants in the Naxyris Loan Agreement relate to, among other items: (i) payment of taxes; (ii) financial reporting; (iii) maintenance of insurance; and (iv) limitations on indebtedness, liens, mergers, consolidations and acquisitions, transfers of assets, dividends and other distributions in respect of capital stock, investments, loans and advances, and corporate changes. The Naxyris Loan Agreement also contains financial covenants, including covenants related to minimum revenue, liquidity, and asset coverage. September 2019 On September 10, 2019, $12.5 September 10, 2019 $12.5 12% September 10, 2019, March 31, June 30, September 30 December 31, December 31, 2019, January 1, 2023. may 100% In connection with the entry into the Investor Credit Agreements, on September 10, 2019, 3,205,128 $3.90 two 4 2 not six not no may 9.99% 60 120 no 144 not 10%, 5% 90 $3.31 $3.90 In connection with the entry into the Investor Credit Agreements and the issuance of the warrants, on September 10, 2019, no 6.99% third Ginkgo Note Amendment On September 29, 2019, November 2017 5, 10, 8 2018 10 November 2017 10.5% 12% October 1, 2019 $1.3 December 15, 2019 March 31, 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Liquidity [Policy Text Block]	Going Concern The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations for at least the next 12 March 31, 2019, $199.4 $119.5 December 31, 2018 $1.6 As of March 31, 2019, $13.5 $215.8 $153.8 March 31, 2019, 12, March 31, 2020 $179.8 $23.5 Cash and cash equivalents of $5.2 March 31, 2019 not March 31, 2020. one not twelve March 31, 2020 December 31, 2018, may may not On September 16, 2019, $63.6 The Company does not not no no not not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of renewable products, licenses of and royalties from intellectual property, and grants and collaborative research and development services. Revenue is measured based on the consideration specified in a contract with a customer and recognized when, or as, the Company satisfies a performance obligation by transferring control over a product or service to a customer. The Company generally does not The Company accounts for a contract when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance and collectability of the consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators among others when determining whether it is acting as a principal in the transaction and recording revenue on a gross basis: (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer and (iii) the Company has discretion in establishing the price for the specified good or service. If a transaction does not The Company’s significant contracts and contractual terms with its customers are presented in Note 10, 8 2018 10 The Company recognizes revenue when control has passed to the customer. The following indicators are evaluated in determining when control has passed to the customer: (i) the Company has a right to payment for the product or service, (ii) the customer has legal title to the product, (iii) the Company has transferred physical possession of the product to the customer, (iv) the customer has the significant risk and rewards of ownership of the product and (v) the customer has accepted the product. The Company’s renewable products are delivered to customers from the Company’s facilities with shipping terms typically specifying F.O.B. shipping point. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company's contracts may The following is a description of the principal goods and services from which the Company generates revenue. Renewable Product Sales Revenues from renewable product sales are recognized as a distinct performance obligation on a gross basis as the Company is acting as a principal in these transactions, with the selling price to the customer recorded net of discounts and allowances. Revenues are recognized at a point in time when control has passed to the customer, which typically is upon the renewable products leaving the Company’s facilities with the first may not not not two not Licenses and Royalties Licensing of Intellectual Property: Royalties from Licensing of Intellectual Property: When the Company’s intellectual property license is the only performance obligation, or it is the predominant performance obligation in arrangements with multiple performance obligations, the Company applies the sales-based royalty exception and revenue is estimated and recognized at a point in time when the licensee’s product sales occur. Estimates of sales-based royalty revenues are made using the most likely amount method, which is the single amount in a range of possible amounts derived from the licensee’s historical sales volumes and sales prices of its products and recent commodity market pricing data and trends. When the Company’s intellectual property license is not not Grants and Collaborative Research and Development Services Collaborative Research and Development Services: one Collaboration agreements are evaluated at inception to determine whether the intellectual property licenses represent distinct performance obligations separate from the research and development services. If the licenses are determined to be distinct, the non-refundable upfront license fee is recognized as revenue at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license while the research and development service fees are recognized over time as the performance obligations are satisfied. The research and development service fees represent variable consideration. Estimates of the amount of variable consideration to include in the transaction price are made using the expected value method, which is the sum of probability-weighted amounts in a range of possible amounts. The Company only includes an amount of variable consideration in the transaction price to the extent it is probable that a significant reversal in the cumulative revenue recognized will not Collaboration agreements that include milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not The Company generally invoices its collaborators on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Contract liability arises from amounts received in advance of performing the research and development activities and is recognized as revenue in future periods as the performance obligations are satisfied. Grants: The milestone payments are evaluated at inception to determine whether the milestone events are considered probable of achievement and estimates are made of the amount of the milestone payments to include in the transaction price using the most likely amount method which is the single amount in a range of possible amounts. If it is probable that a significant revenue reversal will not For descriptions of the Company's other significant accounting policies, see the 2018 10
New Accounting Pronouncements, Policy [Policy Text Block]	Accounting Standards or Updates Recently Adopted In the three March 31, 2019, Leases February 2016, No. 2016 02, Leases (Topic 842 July 2018, 2018 11, Leases (Topic 842 842 The Company adopted this standard on January 1, 2019 1 2 3 not not not not not 12 not The adoption of this standard had the effect of increasing assets and liabilities on the condensed consolidated balance sheet by $25.7 not 1 2 Upon adoption, the Company recognized operating lease liabilities of $33.6 $29.7 Financial Instruments with "Down Round" Features July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 no first 2019, 2017 11 $32.5 $8.5 $41.0 Recent Accounting Standards or Updates Not Fair Value Measurement August 2018, 2018 13, Fair Value Measurement (Topic 820 820, Fair Value Measurement 2018 13 first 2020, Collaborative Revenue Arrangements November 2018, 2018 18, Clarifying the Interaction between Topic 808 606 606, two first 2020 not Credit Losses June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 2016 13 first 2020. not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may

Note 2 - Balance Sheet Details

Note 2 - Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Raw materials $ 2,451 $ 3,901 Work-in-process 238 539 Finished goods 5,797 5,253 Inventories $ 8,486 $ 9,693
Deferred Cost of Products Sold Disclosure [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Deferred cost of products sold - related party $ 1,489 $ 489 Deferred cost of products sold, noncurrent - related party 9,001 2,828 Total $ 10,490 $ 3,317
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Prepayments, advances and deposits $ 3,310 $ 5,644 Recoverable taxes from Brazilian government entities 956 631 Other 3,949 4,291 Total prepaid expenses and other current assets $ 8,215 $ 10,566
Property, Plant and Equipment [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Machinery and equipment $ 45,874 $ 43,713 Leasehold improvements 39,951 39,922 Computers and software 10,138 9,987 Furniture and office equipment, vehicles and land 3,279 3,016 Construction in progress 1,460 1,749 Total property, plant and equipment, gross 100,702 98,387 Less: accumulated depreciation and amortization (79,144 ) (78,631 ) Property, plant and equipment, net $ 21,558 $ 19,756
Lease, Cost [Table Text Block]	Amounts in thousands Three Months Ended March 31, 2019 Cash paid for operating lease liabilities $ 5,305 Right-of-use assets obtained in exchange for new operating lease obligations (1) $ 30,472 Weighted-average remaining lease term (in years) 2.7 Weighted-average discount rate 18.0 %
Lessee, Lease Liability, Maturity [Table Text Block]	Years ending December 31: Financing Leases Operating Total Leases 2019 (remaining nine months) $ 368 $ 12,755 $ 13,123 2020 199 9,109 9,308 2021 1 7,226 7,227 2022 — 7,398 7,398 2023 — 3,034 3,034 Thereafter — — — Total lease payments 568 39,522 40,090 Less: amount representing interest (23 ) (9,793 ) (9,816 ) Total lease liability $ 545 $ 29,729 $ 30,274 Current lease liability $ 452 $ 10,972 $ 11,424 Noncurrent lease liability 93 18,757 18,850 Total lease liability $ 545 $ 29,729 $ 30,274
Schedule of Other Assets, Noncurrent [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Contingent consideration $ 4,286 $ 4,286 Deposits 145 2,465 Other 1,117 1,207 Other assets $ 5,548 $ 7,958
Schedule of Accrued and Other Current Liabilities [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 DSM manufacturing capacity fee $ 7,250 $ — Contract termination fees 5,337 6,247 Accrued interest 7,094 3,853 Payroll and related expenses 5,285 9,220 Asset retirement obligation 3,111 3,063 Tax-related liabilities 2,589 2,139 Professional services 1,871 1,173 Other 1,054 3,284 Total accrued and other current liabilities $ 33,591 $ 28,979
Other Noncurrent Liabilities [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Contract termination fees, net of current portion $ 8,207 $ 7,715 Liability for unrecognized tax benefit 6,582 6,582 Contract liability, net of current portion (Note 9) 1,449 1,587 Deferred rent, net of current portion (1) — 6,440 Other 682 868 Total other noncurrent liabilities $ 16,920 $ 23,192

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities 6% Convertible Notes Due 2021 $ — $ — $ 60,048 $ 60,048 $ — $ — $ 57,918 $ 57,918 Freestanding derivative instruments in connection with the issuance of equity instruments — — 3,798 3,798 — — 42,796 42,796 Total liabilities measured and recorded at fair value $ — $ — $ 63,846 $ 63,846 $ — $ — $ 100,714 $ 100,714
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	In thousands Fair value at December 31, 2018 $ 57,918 Change in fair value 2,130 Fair value at March 31, 2019 $ 60,048
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(In thousands) Equity-related Derivative Liability Debt-related Derivative Liability Total Derivative Liability Balance at December 31, 2018 $ 41,272 $ 1,524 $ 42,796 Derecognition upon adoption of ASU 2017-11 (39,513 ) (1,524 ) (41,037 ) Change in fair value of derivative liabilities 2,039 — 2,039 Balance at March 31, 2019 $ 3,798 $ — $ 3,798

Note 4 - Debt (Tables)

Note 4 - Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Debt [Table Text Block]	March 31, 2019 December 31, 2018 (In thousands) Principal Unamortized Debt (Discount) Premium Change in Fair Value Net Balance Principal Unamortized Debt (Discount) Premium Change in Fair Value Net Balance Convertible notes payable 6% convertible notes due 2021 $ 60,000 $ — $ 48 $ 60,048 $ 60,000 $ — $ (2,082 ) $ 57,918 2015 Rule 144A convertible notes 37,887 (358 ) — 37,529 37,887 (2,413 ) — 35,474 2014 Rule 144A convertible notes 24,004 (289 ) — 23,715 24,004 (867 ) — 23,137 August 2013 financing convertible note 4,863 (596 ) — 4,267 4,415 (70 ) — 4,345 126,754 (1,243 ) 48 125,559 126,306 (3,350 ) (2,082 ) 120,874 Related party convertible notes payable 2014 Rule 144A convertible notes 24,705 (346 ) — 24,359 24,705 (1,038 ) — 23,667 Loans payable and credit facilities GACP secured term loan facility 36,000 (1,208 ) — 34,792 36,000 (1,349 ) — 34,651 Ginkgo note 12,000 (3,832 ) — 8,168 12,000 (4,047 ) — 7,953 Other loans payable 4,813 (1,011 ) — 3,802 4,910 (1,047 ) — 3,863 52,813 (6,051 ) — 46,762 52,910 (6,443 ) — 46,467 Related party loans payable DSM note 25,000 (5,853 ) — 19,147 25,000 (6,311 ) — 18,689 Total debt $ 229,272 $ (13,493 ) $ 48 215,827 $ 228,921 $ (17,142 ) $ (2,082 ) 209,697 Less: current portion (153,752 ) (147,677 ) Long-term debt, net of current portion $ 62,075 $ 62,020
Schedule of Long-term Debt Instruments [Table Text Block]	(In thousands) Convertible Loans Related Related Total 2019 (remaining nine months) $ 139,303 $ 9,689 $ 25,618 $ 1,875 $ 176,485 2020 — 10,113 — 2,500 12,613 2021 — 34,776 — 28,146 62,922 2022 — 13,450 — — 13,450 2023 — 399 — — 399 Thereafter — 2,268 — — 2,268 Total future minimum payments 139,303 70,695 25,618 32,521 268,137 Less: amount representing interest (12,303 ) (17,883 ) (913 ) (7,521 ) (38,620 ) Less: future conversion of accrued interest to principal (245 ) — — — (245 ) Present value of minimum debt payments 126,755 52,812 24,705 25,000 229,272 Less: current portion of debt principal (126,755 ) (4,513 ) (24,705 ) — (155,973 ) Noncurrent portion of debt principal $ — $ 48,299 $ — $ 25,000 $ 73,299

Note 5 - Mezzanine Equity (Tabl

Note 5 - Mezzanine Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Mezzanine Equity Table [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Contingently redeemable common stock $ 5,000 $ 5,000

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Transaction Number Outstanding as of December 31, 2018 Additional Warrants Issued Exercises Number Outstanding as of March 31, 2019 August 2018 warrant exercise agreements 12,097,164 — — 12,097,164 May 2017 cash and dilution warrants 6,292,798 — — 6,292,798 August 2017 cash and dilution warrants 3,968,116 — — 3,968,116 April 2018 warrant exercise agreements 3,616,174 — — 3,616,174 July 2015 related party debt exchange 663,228 — (471,204 ) 192,024 February 2016 related party private placement 171,429 — — 171,429 July 2015 private placement 81,197 — (8,547 ) 72,650 Other 1,406 — — 1,406 26,891,512 — (479,751 ) 26,411,761

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, (In thousands, except shares and per share amounts) 2019 2018 Numerator: Net loss attributable to Amyris, Inc. $ (66,243 ) $ (92,802 ) Less: losses allocated to participating securities 2,430 7,504 Net loss attributable to Amyris, Inc. common stockholders $ (63,813 ) $ (85,298 ) Denominator: Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted 77,512,059 51,200,922 Loss per share attributable to common stockholders, basic and diluted $ (0.82 ) $ (1.67 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2019 2018 Period-end stock options to purchase common stock 5,427,384 1,365,447 Convertible promissory notes (1) 12,699,607 8,347,364 Period-end common stock warrants 26,411,761 29,759,452 Period-end restricted stock units 5,493,579 706,697 Period-end preferred stock 2,955,732 4,504,212 Total potentially dilutive securities excluded from computation of diluted loss per share 52,988,063 44,683,172

Note 9 - Revenue Recognition _2

Note 9 - Revenue Recognition and Contract Assets and Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, (In thousands) 2019 2018 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 7,073 $ — $ 493 $ 7,566 $ 1,962 $ — $ 1,209 $ 3,171 Europe 2,854 118 1,629 4,601 2,434 7,955 3,500 13,889 Asia 1,718 — 250 1,968 678 — — 678 South America 220 — — 220 21 — — 21 Other 19 — — 19 100 — — 100 $ 11,884 $ 118 $ 2,372 $ 14,374 $ 5,195 $ 7,955 $ 4,709 $ 17,859
Revenue in Connection with Significant Revenue Agreement [Table Text Block]	Three Months Ended March 31, (In thousands) 2019 2018 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total Firmenich $ 1,891 $ 498 $ 728 $ 3,117 $ 207 $ 37 $ 1,267 $ 1,511 Givaudan 1,575 — — 1,575 1,076 — 1,500 2,576 American Sugar Refining 1,494 — — 1,494 — — — — DSM - related party 2 (380 ) 396 18 — 7,918 734 8,652 Subtotal revenue from significant revenue agreements 4,962 118 1,124 6,204 1,283 7,955 3,501 12,739 Revenue from all other customers 6,922 — 1,248 8,170 3,912 — 1,208 5,120 Total revenue from all customers $ 11,884 $ 118 $ 2,372 $ 14,374 $ 5,195 $ 7,955 $ 4,709 $ 17,859
Contract with Customer, Asset and Liability [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Accounts receivable, net $ 10,968 $ 16,003 Accounts receivable - related party, net $ 1,334 $ 1,349 Accounts receivable, unbilled - related party $ — $ 8,021 Accounts receivable, unbilled, noncurrent - related party $ 1,203 $ 1,203 Contract liabilities $ 8,333 $ 8,236 Contract liabilities, noncurrent (1) $ 1,449 $ 1,587
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	(In thousands) As of March 31, 2019 Remaining 2019 $ 23,920 2020 38,508 2021 31,172 2022 and thereafter — Total from all customers $ 93,600

Note 10 - Related Party Trans_2

Note 10 - Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Related Party Accounts Receivables [Table Text Block]	(In thousands) March 31, 2019 December 31, 2018 Accounts receivable: DSM $ 1,334 $ 1,071 Novvi — 188 Total — 90 $ 1,334 $ 1,349 Accounts receivable, unbilled, current: DSM $ — $ 8,021 Accounts receivable, unbilled, noncurrent: DSM $ 1,203 $ 1,203

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]	Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2018 5,390,270 $ 11.55 8.5 $ 29 Granted 104,452 $ 4.73 Exercised (3,612 ) $ 3.68 Forfeited or expired (63,726 ) $ 14.27 Outstanding - March 31, 2019 5,427,384 $ 11.39 8.3 $ — Vested or expected to vest after March 31, 2019 4,874,155 $ 12.10 8.3 $ — Exercisable at March 31, 2019 977,466 $ 39.20 5.8 $ —
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2018 5,294,803 $ 5.50 1.7 Awarded 493,790 $ 4.65 RSUs released (192,795 ) $ 6.55 RSUs forfeited (102,219 ) $ 5.61 Outstanding - March 31, 2019 5,493,579 $ 5.38 1.5 Vested or expected to vest after March 31, 2019 5,153,107 $ 5.39 1.5
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, (In thousands) 2019 2018 Research and development $ 663 $ 363 Sales, general and administrative 2,789 915 Total stock-based compensation expense $ 3,452 $ 1,278

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	Jan. 01, 2019	Sep. 16, 2019	Mar. 31, 2019	Dec. 31, 2018
Working Capital			$ (199,400,000)	$ (119,500,000)
Retained Earnings (Accumulated Deficit), Ending Balance			(1,579,129,000)	(1,521,417,000)
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total			13,500,000
Long-term Debt, Total			215,827,000	209,697,000
Long-term Debt, Current Maturities, Including Due to Related Parties			153,752,000	147,677,000
Long-term Debt, Current Maturities Due Within 60 Days, Including Due to Related Parties			179,800,000
Long-term Debt, Current Maturities Due Within 60 Days, Including Due to Related Parties, Anticipated Interest Portion			23,500,000
Cash, Cash Equivalents, and Short-term Investments, Total			5,200,000
Assets, Total			105,147,000	127,925,000
Operating Lease, Liability, Total			29,729,000
Operating Lease, Right-of-Use Asset	$ 800,000		27,645,000
Liabilities, Total			$ 337,347,000	$ 339,744,000
Accounting Standards Update 2016-02 [Member]
Assets, Total	25,700,000
Operating Lease, Liability, Total	33,600,000
Operating Lease, Right-of-Use Asset	29,700,000
Liabilities, Total	24,900,000
Accounting Standards Update 2017-11 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance	(8,500,000)
Additional Paid in Capital, Ending Balance	32,500,000
Increase (Decrease) in Derivative Liabilities	$ (41,000,000)
Convertible Senior Notes, 6.0%, Due in 2021, Second Exchange [Member] | Subsequent Event [Member]
Debt Instrument, Debt Default, Amount		$ 63,600,000

Note 2 - Balance Sheet Detail_2

Note 2 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jan. 01, 2019	Dec. 31, 2018
Manufacturing Capacity Reservation Fee Current	$ 7,250
Deferred Cost of Products Sold, Related Party	10,490			3,317
Capitalized Computer Software, Additions	200
Operating Lease, Right-of-Use Asset	27,645		$ 800
Operating Lease, Liability, Total	29,729
Operating Lease, Expense	2,800
Finance Lease, Right-of-use Asset, Accumulated Amortization	2,500			2,300
Property, Plant and Equipment, Net [Member]
Finance Lease, Right-of-Use Asset	5,300			5,000
Cost of Sales [Member]
Operating Lease, Expense	$ 1,800
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			29,700
Operating Lease, Liability, Total			$ 33,600
Minimum [Member]
Lessee Operating Lease, Remaining Lease Term	1 year
Lessee, Operating Lease, Renewal Term	1 year
Maximum [Member]
Lessee Operating Lease, Remaining Lease Term	5 years
Lessee, Operating Lease, Renewal Term	5 years
Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 800	$ 1,600
DSM International B.V. [Member]
Manufacturing Capacity Reservation Fee Current				24,400
Deferred Cost of Products Sold, Related Party	13,800			$ 3,300
Payments of Reservation Capacity Fees	$ 7,300

Note 2 - Balance Sheet Detail_3

Note 2 - Balance Sheet Details - Inventory, Current (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Raw materials	$ 2,451	$ 3,901
Work-in-process	238	539
Finished goods	5,797	5,253
Inventories	$ 8,486	$ 9,693

Note 2 - Balance Sheet Detail_4

Note 2 - Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Deferred cost of products sold - related party	$ 1,489	$ 489
Deferred cost of products sold, noncurrent - related party	9,001	2,828
Total	$ 10,490	$ 3,317

Note 2 - Balance Sheet Detail_5

Note 2 - Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Prepayments, advances and deposits	$ 3,310	$ 5,644
Recoverable taxes from Brazilian government entities	956	631
Other	3,949	4,291
Total prepaid expenses and other current assets	$ 8,215	$ 10,566

Note 2 - Balance Sheet Detail_6

Note 2 - Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Property, plant and equipment	$ 100,702	$ 98,387
Less: accumulated depreciation and amortization	(79,144)	(78,631)
Property, plant and equipment, net	21,558	19,756
Machinery and Equipment [Member]
Property, plant and equipment	45,874	43,713
Leasehold Improvements [Member]
Property, plant and equipment	39,951	39,922
Computer Equipment and Software [Member]
Property, plant and equipment	10,138	9,987
Furniture and Office Equipment, Vehicles and Land [Member]
Property, plant and equipment	3,279	3,016
Construction in Progress [Member]
Property, plant and equipment	$ 1,460	$ 1,749

Note 2 - Balance Sheet Detail_7

Note 2 - Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Cash paid for operating lease liabilities	$ 5,305
Right-of-use assets obtained in exchange for new operating lease obligations(1)	$ 30,472	[1]
Weighted-average remaining lease term (in years) (Year)	2 years 255 days
Weighted-average discount rate	18.00%
[1]	Includes $26.7 million for operating leases existing on January 1, 2019 and $0.9 million for operating leases that commenced in the first quarter of 2019.

Note 2 - Balance Sheet Detail_8

Note 2 - Balance Sheet Details - Maturities of Financing and Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
2019 (remaining nine months), financing leases	$ 368
2019 (remaining nine months), operating leases	12,755
2019 (remaining nine months), total leases	13,123
2020, financing leases	199
2020, operating leases	9,109
2020, total leases	9,308
2021, financing leases	1
2021, operating leases	7,226
2021, total leases	7,227
2022, financing leases
2022, operating leases	7,398
2022, total leases	7,398
2023, financing leases
2023, operating leases	3,034
2023, total leases	3,034
Thereafter, financing leases
Thereafter, operating leases
Thereafter, total leases
Total lease payments, financing leases	568
Total lease payments, operating leases	39,522
Total lease payments, total leases	40,090
Less: amount representing interest	(23)
Less: amount representing interest	(9,793)
Less: amount representing interest	(9,816)
Total lease liability, financing leases	545
Total lease liability, operating leases	29,729
Total lease liability, total leases	30,274
Current lease liability, financing leases	452
Current lease liability, operating leases	10,972
Current lease liability, total leases	11,424
Noncurrent lease liability, financing leases	93
Noncurrent lease liability, operating leases	18,757
Noncurrent lease liability, total leases	18,850
Total lease liability, financing leases	545
Operating Lease, Liability, Total	$ 29,729

Note 2 - Balance Sheet Detail_9

Note 2 - Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Contingent consideration	$ 4,286	$ 4,286
Deposits	145	2,465
Other	1,117	1,207
Other assets	$ 5,548	$ 7,958

Note 2 - Balance Sheet Detai_10

Note 2 - Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
DSM manufacturing capacity fee	$ 7,250
Contract termination fees	5,337	6,247
Accrued interest	7,094	3,853
Payroll and related expenses	5,285	9,220
Asset retirement obligation	3,111	3,063
Tax-related liabilities	2,589	2,139
Professional services	1,871	1,173
Other	1,054	3,284
Total accrued and other current liabilities	$ 33,591	$ 28,979

Note 2 - Balance Sheet Detai_11

Note 2 - Balance Sheet Details - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Contract termination fees, net of current portion	$ 8,207	$ 7,715
Liability for unrecognized tax benefit	6,582	6,582
Contract liability, net of current portion (Note 9)	1,449	1,587
Deferred rent, net of current portion(1)		6,440
Other	682	868
Total other noncurrent liabilities	$ 16,920	$ 23,192

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurement (Details Textual)	3 Months Ended
	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 10, 2018USD ($)
Long-term Debt, Gross	$ 229,272,000	$ 228,921,000
Long-term Debt, Fair Value	60,048,000	$ 57,918,000
Debt, Long-term and Short-term, Combined Amount, Total	155,800,000
Debt Instrument, Fair Value Disclosure, Total	155,800,000
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Debt Instrument, Face Amount			$ 60,000,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%	6.00%
Long-term Debt, Gross	60,000,000
Long-term Debt, Fair Value	60,000,000
Fair Value Adjustment of Debt	$ (2,100,000)
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Discount Rate [Member]
Long-term Debt, Measurement Input	0.238
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Price Volatility [Member]
Long-term Debt, Measurement Input	0.45
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Probability of Principal Repayment in Cash [Member]
Long-term Debt, Measurement Input	0.5
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Probability of Principal Repayment in Stock [Member]
Long-term Debt, Measurement Input	0.5
Convertible Senior Notes, 6.0% Due in 2021 [Member] | Measurement Input, Probability of Change in Control [Member]
Long-term Debt, Measurement Input	0.05

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Debt, current portion, fair value	$ 60,048	$ 57,918
Fair Value, Recurring [Member]
Debt, current portion, fair value	60,048	57,918
Freestanding derivative instruments in connection with the issuance of equity instruments	3,798	42,796
Total liabilities measured and recorded at fair value	63,846	100,714
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Debt, current portion, fair value
Freestanding derivative instruments in connection with the issuance of equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Debt, current portion, fair value
Freestanding derivative instruments in connection with the issuance of equity instruments
Total liabilities measured and recorded at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Debt, current portion, fair value	60,048	57,918
Freestanding derivative instruments in connection with the issuance of equity instruments	3,798	42,796
Total liabilities measured and recorded at fair value	$ 63,846	$ 100,714

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurement - Convertible Debt (Details) - Long-term Debt [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Fair value	$ 57,918
Change in fair value	2,130
Fair value	$ 60,048

Note 3 - Fair Value Measureme_6

Note 3 - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Fair value	$ 42,796
Derecognition upon adoption of ASU 2017-11	(41,037)
Change in fair value	2,039
Fair value	3,798
Equity Securities [Member]
Fair value	41,272
Derecognition upon adoption of ASU 2017-11	(39,513)
Change in fair value	2,039
Fair value	3,798
Debt Securities [Member]
Fair value	1,524
Derecognition upon adoption of ASU 2017-11	(1,524)
Change in fair value
Fair value

Note 4 - Debt (Details Textual)

Note 4 - Debt (Details Textual) - Second Tranche [Member] - Related Party Convertible Notes [Member] - USD ($) $ in Millions	Jul. 15, 2019	Jan. 14, 2019
Debt Instrument, Cash Waiver Fee Amount Payable		$ 0.6
Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage	1.75%

Note 4 - Debt - Debt Components

Note 4 - Debt - Debt Components (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Principal	$ 229,272,000		$ 228,921,000
Unamortized Debt Premium	(13,493,000)		(17,142,000)
Loss from change in fair value of debt	48,000		(2,082,000)
Net Balance	215,827,000		209,697,000
Net Balance	(153,752,000)		(147,677,000)
Net Balance	62,075,000		62,020,000
Convertible Senior Notes, 6.0% Due in 2021 [Member]
Principal	60,000,000
Convertible Debt [Member]
Principal	126,754,000		126,306,000
Unamortized Debt Premium	(1,243,000)		(3,350,000)
Loss from change in fair value of debt	48,000		(2,082,000)
Net Balance	125,559,000		120,874,000
Convertible Debt [Member] | Convertible Senior Notes, 6.0% Due in 2021 [Member]
Principal	60,000,000		60,000,000
Unamortized Debt Premium
Loss from change in fair value of debt	48,000		(2,082,000)
Net Balance	60,048,000		57,918,000
Convertible Debt [Member] | The 2015 144A Notes [Member]
Principal	37,887,000		37,887,000
Unamortized Debt Premium	(358,000)		(2,413,000)
Loss from change in fair value of debt
Net Balance	37,529,000		35,474,000
Convertible Debt [Member] | The 2014 144A Notes [Member]
Principal	24,004,000		24,004,000
Unamortized Debt Premium	(289,000)		(867,000)
Loss from change in fair value of debt
Net Balance	23,715,000		23,137,000
Convertible Debt [Member] | August 2013 Convertible Notes [Member]
Principal	4,863,000		4,415,000
Unamortized Debt Premium	(596,000)		(70,000)
Loss from change in fair value of debt
Net Balance	4,267,000		4,345
Related Party Convertible Notes [Member] | The 2014 144A Notes [Member]
Principal	24,705,000		24,705,000
Unamortized Debt Premium	(346,000)		(1,038,000)
Loss from change in fair value of debt
Net Balance	24,359,000		23,667,000
Nonrelated Party Debt [Member]
Principal	36,000,000		36,000,000
Unamortized Debt Premium	(1,208,000)		(1,349,000)
Loss from change in fair value of debt
Net Balance	34,792,000		34,651,000
Loans Payable [Member]
Principal	52,813,000		52,910,000
Unamortized Debt Premium	(6,051,000)		(6,443,000)
Loss from change in fair value of debt
Net Balance	46,762,000		46,467,000
Loans Payable [Member] | Ginkgo Collaboration Note [Member]
Principal	12,000,000		12,000,000
Unamortized Debt Premium	(3,832,000)		(4,047,000)
Loss from change in fair value of debt
Net Balance	8,168,000		7,953,000
Loans Payable [Member] | Other Loans Payable [Member]
Principal	4,813,000		4,910,000
Unamortized Debt Premium	(1,011,000)		(1,047,000)
Loss from change in fair value of debt
Net Balance	3,802,000		3,863,000
Related Party Loan Payable [Member] | DSM Note [Member]
Principal	25,000,000		25,000,000
Unamortized Debt Premium	(5,853,000)		(6,311,000)
Loss from change in fair value of debt
Net Balance	$ 19,147,000		$ 18,689,000

Note 4 - Debt - Long-term Debt

Note 4 - Debt - Long-term Debt Instruments (Details) $ in Thousands	Mar. 31, 2019USD ($)
2019 (remaining nine months)	$ 176,485
2020	12,613
2021	62,922
2022	13,450
2023	399
Thereafter	2,268
Total future minimum payments	268,137
Less: amount representing interest	(38,620)
Less: future conversion of accrued interest to principal	(245)
Present value of minimum debt payments	229,272
Less: current portion of debt principal	(155,973)
Noncurrent portion of debt principal	73,299
Convertible Debt [Member]
2019 (remaining nine months)	139,303
2020
2021
2022
2023
Thereafter
Total future minimum payments	139,303
Less: amount representing interest	(12,303)
Less: future conversion of accrued interest to principal	(245)
Present value of minimum debt payments	126,755
Less: current portion of debt principal	(126,755)
Noncurrent portion of debt principal
Loans Payable and Credit Facilities [Member]
2019 (remaining nine months)	9,689
2020	10,113
2021	34,776
2022	13,450
2023	399
Thereafter	2,268
Total future minimum payments	70,695
Less: amount representing interest	(17,883)
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	52,812
Less: current portion of debt principal	(4,513)
Noncurrent portion of debt principal	48,299
Related Party Convertible Notes [Member]
2019 (remaining nine months)	25,618
2020
2021
2022
2023
Thereafter
Total future minimum payments	25,618
Less: amount representing interest	(913)
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	24,705
Less: current portion of debt principal	(24,705)
Noncurrent portion of debt principal
Related Party Loans Payable and Credit Facilities [Member]
2019 (remaining nine months)	1,875
2020	2,500
2021	28,146
2022
2023
Thereafter
Total future minimum payments	32,521
Less: amount representing interest	(7,521)
Less: future conversion of accrued interest to principal
Present value of minimum debt payments	25,000
Less: current portion of debt principal
Noncurrent portion of debt principal	$ 25,000

Note 5 - Mezzanine Equity (Deta

Note 5 - Mezzanine Equity (Details Textual) - Gates Foundation Purchase Agreement [Member] - USD ($) $ / shares in Units, $ in Millions	Apr. 08, 2016	Mar. 31, 2019
Share Price	$ 17.10
Compound Annual Return	10.00%
Research and Development Obligation, Remaining Amount		$ 0.6

Note 5 - Mezzanine Equity - Mez

Note 5 - Mezzanine Equity - Mezzanine Equity (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Mezzanine Equity	$ 5,000	$ 5,000
Contingently Redeemable Common Stock [Member]
Mezzanine Equity	$ 5,000	$ 5,000

Note 6 - Stockholders' Defici_2

Note 6 - Stockholders' Deficit (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock Issued During Period, Shares, Warrants Exercised	479,751
Proceeds from Warrant Exercises	$ 1	$ 133
August 2017 Vito Dilution Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised	479,751
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Proceeds from Warrant Exercises	$ 0
Stock Issued During Period, Shares, Warrants Exercised Through Net Share Settlement	450,568

Note 6 - Stockholders' Defici_3

Note 6 - Stockholders' Deficit - Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2019shares
Number outstanding, beginning balance (in shares)	26,891,512
Additional Warrants Issued (in shares)
Exercises (in shares)	(479,751)
Number outstanding, ending balance (in shares)	26,411,761
Warrant 6 [Member]
Number outstanding, beginning balance (in shares)	12,097,164
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	12,097,164
Warrant 4 [Member]
Number outstanding, beginning balance (in shares)	6,292,798
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	6,292,798
Warrant 5 [Member]
Number outstanding, beginning balance (in shares)	3,968,116
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	3,968,116
Warrant 7 [Member]
Number outstanding, beginning balance (in shares)	3,616,174
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	3,616,174
Warrant 2 [Member]
Number outstanding, beginning balance (in shares)	663,228
Additional Warrants Issued (in shares)
Exercises (in shares)	(471,204)
Number outstanding, ending balance (in shares)	192,024
Warrant 3 [Member]
Number outstanding, beginning balance (in shares)	171,429
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	171,429
Warrant 1 [Member]
Number outstanding, beginning balance (in shares)	81,197
Additional Warrants Issued (in shares)
Exercises (in shares)	(8,547)
Number outstanding, ending balance (in shares)	72,650
Warrant 8 [Member]
Number outstanding, beginning balance (in shares)	1,406
Additional Warrants Issued (in shares)
Exercises (in shares)
Number outstanding, ending balance (in shares)	1,406

Note 7 - Loss Per Share - Calcu

Note 7 - Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net loss	$ (66,243)	$ (92,802)
Less: losses allocated to participating securities	2,430	7,504
Net loss attributable to Amyris, Inc. common stockholders	$ (63,813)	$ (85,298)
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares)	77,512,059	51,200,922
Loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.82)	$ (1.67)

Note 7 - Loss Per Share - Antid

Note 7 - Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Antidilutive securities (in shares)		52,988,063	44,683,172
Stock Options to Purchase Common Stock [Member]
Antidilutive securities (in shares)		5,427,384	1,365,447
Convertible Promissory Notes [Member]
Antidilutive securities (in shares)	[1]	12,699,607	8,347,364
Period-end Common Stock Warrants [Member]
Antidilutive securities (in shares)		26,411,761	29,759,452
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)		5,493,579	706,697
Period-end Preferred Stock [Member]
Antidilutive securities (in shares)		2,955,732	4,504,212
[1]	The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 9 - Revenue Recognition _3

Note 9 - Revenue Recognition and Contract Assets and Liabilities 1 (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Contract with Customer, Asset, Reclassified to Receivable	$ 8,000
Cost of Goods and Services Sold, Total	17,707	$ 5,315
Interest Expense, Total	12,534	$ 9,978
Revenue, Remaining Performance Obligation, Constrained Variable Consideration, Amount	17,600
DSM International B.V. [Member]
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price	600
Proceeds from Customers	7,400
Interest Expense, Total	200
DSM International B.V. [Member] | Licenses and Royalties [Member]
Cost of Goods and Services Sold, Total	$ 400

Note 9 - Revenue Recognition _4

Note 9 - Revenue Recognition and Contract Assets and Liabilities 2 (Details Textual)	Mar. 31, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	273 days
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Note 9 - Revenue Recognition _5

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenues	$ 14,374	$ 17,859	$ 17,859
Renewable Products [Member]
Revenues	11,884	5,195	5,195
Licenses and Royalties [Member]
Revenues	118	7,955	7,955
Grants and Collaborations [Member]
Revenues	2,372	$ 4,709	4,709
UNITED STATES
Revenues	7,566		3,171
UNITED STATES | Renewable Products [Member]
Revenues	7,073		1,962
UNITED STATES | Licenses and Royalties [Member]
Revenues
UNITED STATES | Grants and Collaborations [Member]
Revenues	493		1,209
Europe [Member]
Revenues	4,601		13,889
Europe [Member] | Renewable Products [Member]
Revenues	2,854		2,434
Europe [Member] | Licenses and Royalties [Member]
Revenues	118		7,955
Europe [Member] | Grants and Collaborations [Member]
Revenues	1,629		3,500
Asia [Member]
Revenues	1,968		678
Asia [Member] | Renewable Products [Member]
Revenues	1,718		678
Asia [Member] | Licenses and Royalties [Member]
Revenues
Asia [Member] | Grants and Collaborations [Member]
Revenues	250
South America [Member]
Revenues	220		21
South America [Member] | Renewable Products [Member]
Revenues	220		21
South America [Member] | Licenses and Royalties [Member]
Revenues
South America [Member] | Grants and Collaborations [Member]
Revenues
Other Area [Member]
Revenues	19		100
Other Area [Member] | Renewable Products [Member]
Revenues	19		100
Other Area [Member] | Licenses and Royalties [Member]
Revenues
Other Area [Member] | Grants and Collaborations [Member]
Revenues

Note 9 - Revenue Recognition _6

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenues	$ 14,374	$ 17,859	$ 17,859
Significant Revenue Agreement [Member]
Revenues	6,204	12,739
Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	3,117	1,511
Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues	1,575	2,576
American Refining Group [Member] | Significant Revenue Agreement [Member]
Revenues	1,494
DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	18	8,652
All Other Customers [Member]
Revenues	8,170	5,120
Renewable Products [Member]
Revenues	11,884	5,195	5,195
Renewable Products [Member] | Significant Revenue Agreement [Member]
Revenues	4,962	1,283
Renewable Products [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	1,891	207
Renewable Products [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues	1,575	1,076
Renewable Products [Member] | American Refining Group [Member] | Significant Revenue Agreement [Member]
Revenues	1,494
Renewable Products [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	2
Renewable Products [Member] | All Other Customers [Member]
Revenues	6,922	3,912
Licenses and Royalties [Member]
Revenues	118	7,955	7,955
Licenses and Royalties [Member] | Significant Revenue Agreement [Member]
Revenues	118	7,955
Licenses and Royalties [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	498	37
Licenses and Royalties [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues
Licenses and Royalties [Member] | American Refining Group [Member] | Significant Revenue Agreement [Member]
Revenues
Licenses and Royalties [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	(380)	7,918
Licenses and Royalties [Member] | All Other Customers [Member]
Revenues
Grants and Collaborations [Member]
Revenues	2,372	4,709	$ 4,709
Grants and Collaborations [Member] | Significant Revenue Agreement [Member]
Revenues	1,124	3,501
Grants and Collaborations [Member] | Firmenich [Member] | Significant Revenue Agreement [Member]
Revenues	728	1,267
Grants and Collaborations [Member] | Givaudan International, SA [Member] | Significant Revenue Agreement [Member]
Revenues		1,500
Grants and Collaborations [Member] | American Refining Group [Member] | Significant Revenue Agreement [Member]
Revenues
Grants and Collaborations [Member] | DSM International B.V. [Member] | Significant Revenue Agreement [Member]
Revenues	396	734
Grants and Collaborations [Member] | All Other Customers [Member]
Revenues	$ 1,248	$ 1,208

Note 9 - Revenue Recognition _7

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
Accounts receivable, net		$ 10,968	$ 16,003
Accounts receivable - related party, net		1,334	1,349
Accounts receivable, unbilled - related party			8,021
Accounts receivable, unbilled, noncurrent - related party	[1]	1,203	1,203
Contract liabilities		8,333	8,236
Contract liabilities, noncurrent(1)	[1]	$ 1,449	$ 1,587
[1]	As of March 31, 2019 and December 31, 2018, contract liabilities, noncurrent is presented in Other Noncurrent Liabilities in the consolidated balance sheets because of its insignificance.

Note 9 - Revenue Recognition _8

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) $ in Millions	Mar. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 93.6

Note 9 - Revenue Recognition _9

Note 9 - Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations 2 (Details) $ in Thousands	Mar. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 93,600
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	273 days
Revenue, Remaining Performance Obligation, Amount	$ 23,920
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Amount	$ 38,508
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Amount	$ 31,172
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Amount

Note 10 - Related Party Trans_3

Note 10 - Related Party Transactions (Details Textual)	Mar. 31, 2019
Nikko [Member] | Aprinnova JV [Member]
Equity Method Investment, Ownership Percentage	50.00%

Note 10 - Related Party Trans_4

Note 10 - Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
Accounts receivable, net		$ 1,334	$ 1,349
Contract assets, current			8,021
Contract assets, noncurrent	[1]	1,203	1,203
DSM International B.V. [Member]
Accounts receivable, net		1,334	1,071
Contract assets, current			8,021
Contract assets, noncurrent		1,203	1,203
Novvi LLC [Member]
Accounts receivable, net			188
Total [Member]
Accounts receivable, net			$ 90
[1]	As of March 31, 2019 and December 31, 2018, contract liabilities, noncurrent is presented in Other Noncurrent Liabilities in the consolidated balance sheets because of its insignificance.

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 31.1
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	3 years
Shares, Outstanding, Ending Balance			76,564,829
Equity Incentive Plan, 2010 [Member]
Automatic Annual Increase in the Number of Shares Available for Grant and Issuance		3,828,241
Automatic Annual Increase in Shares Available for Grant and Issuance, Percentage of Outstanding Stock		5.00%
Automatic Annual Increase in the Number of Shares Reserved for Issuance		383,824
Automatic Annual Increase in Shares Reserved for Issuance, Percentage of Outstanding Stock		0.5

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Outstanding (in shares)	5,390,270
Outstanding, weighted average exercise price (in dollars per share)	$ 11.55
Outstanding, weighted average remaining contractual life (Year)	8 years 109 days	8 years 182 days
Outstanding, aggregate intrinsic value		$ 29
Granted (in shares)	104,452
Granted, weighted average exercise price (in dollars per share)	$ 4.73
Exercised (in shares)	(3,612)
Exercised, weighted average exercise price (in dollars per share)	$ 3.68
Forfeited or expired (in shares)	(63,726)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 14.27
Outstanding (in shares)	5,427,384	5,390,270
Outstanding, weighted average exercise price (in dollars per share)	$ 11.39	$ 11.55
Vested or expected to vest (in shares)	4,874,155
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 12.10
Vested and expected to vest, weighted average remaining contractual life (Year)	8 years 109 days
Vested and expected to vest, aggregate intrinsic value
Exercisable (in shares)	977,466
Exercisable, weighted average exercise price (in dollars per share)	$ 39.20
Exercisable, weighted average remaining contractual life (Year)	5 years 292 days
Exercisable, aggregate intrinsic value

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Outstanding, RSUs (in shares)	5,294,803
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 5.50
Outstanding, weighted average remaining contractual life (Year)	1 year 182 days	1 year 255 days
Awarded (in shares)	493,790
Awarded, weighted average grant-date fair value (in dollars per share)	$ 4.65
RSUs released (in shares)	(192,795)
RSUs released, weighted average grant-date fair value (in dollars per share)	$ 6.55
RSUs forfeited (in shares)	(102,219)
RSUs forfeited, weighted average grant-date fair value (in dollars per share)	$ 5.61
Outstanding, RSUs (in shares)	5,493,579	5,294,803
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 5.38	$ 5.50
Vested or expected to vest (in shares)	5,153,107
Vested or expected to vest, weighted average grant-date fair value (in dollars per share)	$ 5.39
Vested or expected to vest, weighted average remaining contractual life (Year)	1 year 182 days

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Allocated share-based compensation expense	$ 3,452	$ 1,278
Research and Development Expense [Member]
Allocated share-based compensation expense	663	363
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 2,789	$ 915

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual)

Sep. 23, 2019USD ($)

Sep. 10, 2019USD ($)$ / sharesshares

Aug. 19, 2019

Aug. 14, 2019USD ($)$ / sharesshares

Aug. 08, 2019USD ($)

Jul. 30, 2019USD ($)

Jul. 26, 2019USD ($)

Jul. 24, 2019USD ($)$ / sharesshares

Jul. 08, 2019shares

Jun. 24, 2019USD ($)shares

May 15, 2019USD ($)$ / sharesshares

May 14, 2019USD ($)$ / sharesshares

May 10, 2019USD ($)$ / sharesshares

May 10, 2019BRL (R$)shares

May 03, 2019USD ($)$ / sharesshares

May 02, 2019USD ($)

Apr. 29, 2019USD ($)$ / sharesshares

Apr. 26, 2019USD ($)$ / sharesshares

Apr. 16, 2019USD ($)$ / sharesshares

Apr. 15, 2019USD ($)

Apr. 04, 2019USD ($)

Jun. 30, 2020USD ($)

Oct. 01, 2019

Sep. 30, 2019

Sep. 29, 2019USD ($)

Sep. 19, 2019USD ($)

Sep. 17, 2019USD ($)

Sep. 16, 2019USD ($)

Aug. 29, 2019USD ($)$ / shares

Aug. 28, 2019$ / shares

Aug. 01, 2019USD ($)

Jul. 29, 2019USD ($)

Jul. 18, 2019

Jul. 10, 2019USD ($)$ / shares

Jun. 11, 2019USD ($)

Apr. 08, 2019USD ($)

Mar. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Dec. 10, 2018USD ($)

Aug. 17, 2018$ / shares

Long-term Debt, Gross

$ 229,272,000

$ 228,921,000

Long-term Debt, Total

215,827,000

209,697,000

July Foris Credit Agreement [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 7.52

Convertible Debt [Member]

Long-term Debt, Gross

126,754,000

126,306,000

Long-term Debt, Total

125,559,000

$ 120,874,000

Convertible Senior Notes, 6.0% Due in 2021 [Member]

Debt Instrument, Interest Rate, Stated Percentage

6.00%

6.00%

Debt Instrument, Face Amount

$ 60,000,000

Long-term Debt, Gross

60,000,000

Convertible Senior Notes, 6.0% Due in 2021 [Member] | Convertible Debt [Member]

Long-term Debt, Gross

60,000,000

$ 60,000,000

Long-term Debt, Total

60,048,000

57,918,000

August 2013 Convertible Notes [Member] | Convertible Debt [Member]

Long-term Debt, Gross

4,863,000

4,415,000

Long-term Debt, Total

$ 4,267,000

$ 4,345

DSM International B.V. [Member] | The 2019 DSM Credit Agreement [Member] | Forecast [Member]

Proceeds from Sale of Equity Securities, Gross, Trigger Repayment of Amounts Outstanding Under Line of Credit

$ 50,000,000

Subsequent Event [Member] | Private Placement [Member]

Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage

19.99%

Proceeds from Issuance of Common Stock

$ 5,000,000

$ 5,800,000

$ 23,200,000

Subsequent Event [Member] | LSA Amendment Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,438,829

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 2.87

Warrants and Rights Outstanding, Term

2 years

Warrant Exercise, Beneficial Common Stock Ownership Maximum Percentage

19.99%

Subsequent Event [Member] | July Foris Credit Agreement [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 2.87

Subsequent Event [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

4.99%

Subsequent Event [Member] | August Foris Credit Agreement [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

4,871,795

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 3.90

Class of Warrant or Right, Term

2 years

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

19.99%

Subsequent Event [Member] | Warrants Issued in Exchange for 6% Convertible Notes Due 2021 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

2,000,000

181,818

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.12

Debt Instrument, Repayment Price, Percent of Face Amount

4.99%

Class of Warrant or Right, Term

2 years

Subsequent Event [Member] | Warrants Issued in Exchange for Convertible Senior Notes, 6.0% Due 2021, Second Exchange [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 2.87

Class of Warrant or Right, Term

2 years

Subsequent Event [Member] | Warrants Issued in Exchange for August 2013 Financing Convertible Note [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,080,000

Class of Warrant or Right, Stock Ownership Percentage, Restriction on Ability to Exercise

4.99%

Subsequent Event [Member] | Investor Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

3,205,128

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 3.90

Warrants and Rights Outstanding, Term

2 years

Warrants or Rights Outstanding, Maximum Percent of Common Stock Outstanding

9.99%

Warrants or Rights Outstanding, Reduction in Exercise Price

10.00%

Warrants or Rights Outstanding, Additional Reduction in Exercise Price

5.00%

Subsequent Event [Member] | Minimum [Member] | Investor Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 3.31

Subsequent Event [Member] | Foris Ventures, LLC [Member]

Related Party Transaction, Purchases from Related Party

$ 2,500,000

Subsequent Event [Member] | Raizen Energia S.A. [Member]

Capital Contribution to the Joint Venture | R$

R$ 2500000

Equity Method Investment, Ownership Percentage

50.00%

Equity Method Investment, Ownership Percentage by Counterparty

50.00%

Subsequent Event [Member] | Raizen Energia S.A. [Member] | Fixed Assets Owned by the Company [Member]

Payments to Acquire Property, Plant, and Equipment, Total

$ 9,000,000

Subsequent Event [Member] | Raizen Energia S.A. [Member] | Fixed Assets From Sao Martinho S.A. [Member]

Payments to Acquire Property, Plant, and Equipment, Total

$ 3,000,000

Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member]

Debt Instrument, Interest Rate, Stated Percentage

4.75%

Long-term Debt, Gross

$ 71,000,000

Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | Unsecured Promissory Note [Member]

Debt Instrument, Face Amount

$ 32,500,000

Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | Base Rate [Member] | Minimum [Member]

Debt Instrument, Basis Spread on Variable Rate

9.00%

Subsequent Event [Member] | Loan and Security Agreement Amendment and Waiver [Member] | Base Rate [Member] | Maximum [Member]

Debt Instrument, Basis Spread on Variable Rate

12.00%

Subsequent Event [Member] | Convertible Senior Notes, 6.0% Due in 2021 [Member]

Debt Instrument, Face Amount

$ 68,300,000

Debt Instrument, Repayment Price, Percent of Face Amount

125.00%

125.00%

Debt Conversion, Original Debt, Amount

$ 4,700,000

$ 53,300,000

$ 4,700,000

$ 53,300,000

Debt Instrument, Penalty for Failure to Make Payment, Premium Increase Percentage

25.00%

Debt Instrument, Periodic Payment, Principal

$ 6,400,000

Subsequent Event [Member] | Convertible Senior Notes, 6.0%, Due in 2021, Second Exchange [Member]

Debt Instrument, Interest Rate, Stated Percentage

18.00%

Debt Instrument, Face Amount

$ 68,300,000

Debt Instrument, Periodic Payment, Principal

$ 3,200,000

Debt Instrument, Debt Default, Amount

$ 63,600,000

Subsequent Event [Member] | August 2013 Convertible Notes [Member] | Convertible Debt [Member]

Debt Conversion, Converted Instrument, Shares Issued | shares

1,767,632

Subsequent Event [Member] | Nikko Loan Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Long-term Debt, Total

$ 5,000,000

Subsequent Event [Member] | Nikko Loan Agreement, First Installment [Member]

Debt Instrument, Face Amount

$ 3,000,000

Proceeds from Issuance of Long-term Debt, Total

2,800,000

Subsequent Event [Member] | Nikko Loan Agreement, Second Installment [Member]

Debt Instrument, Face Amount

$ 2,000,000

Proceeds from Issuance of Long-term Debt, Total

1,900,000

Subsequent Event [Member] | Second Aprinnova Note [Member]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Face Amount

$ 2,018,000,000

Subsequent Event [Member] | The Naxyris Loan Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Face Amount

$ 10,435,000

Debt Instrument, Failure to Pay Fee

6.00%

Subsequent Event [Member] | The Naxyris Loan Agreement [Member] | Interest Wtih Respect to Indebtedness [Member]

Debt Instrument, Basis Spread on Variable Rate

0.25%

Subsequent Event [Member] | The Investor Notes [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Face Amount

$ 12,500,000

Debt Instrument, Early Repayment Amount, Percentage

100.00%

Subsequent Event [Member] | Secured Promissory Note In Connection With Termination of Ginkgo Collaboration Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

10.50%

Debt Instrument, Cash Waiver Fee Amount Payable

$ 1,300,000

Subsequent Event [Member] | Great American Capital Partners, LLC [Member] | Loan and Security Agreement [Member]

Debt Instrument, Requirement, Unrestricted, Unencumbered Cash

$ 15,000,000

Payments for debt agreement amendment

$ 800,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Debt Instrument, Face Amount

$ 8,000,000

Line of Credit Facility, Maximum Borrowing Capacity

8,000,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member] | Minimum [Member]

Debt Instrument, Fee Amount

1,000,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | April Foris Credit Agreement [Member] | Maximum [Member]

Debt Instrument, Fee Amount

$ 500,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | June Foris Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.50%

Debt Instrument, Face Amount

$ 8,500,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 8,500,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | July Foris Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.50%

Debt Instrument, Face Amount

$ 8,000,000

Line of Credit Facility, Maximum Borrowing Capacity

16,000,000

Long-term Line of Credit, Total

$ 8,000,000

$ 8,000,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Foris Credit Agreements [Member]

Debt Instrument, Repayment Price, Percent of Face Amount

100.00%

Subsequent Event [Member] | Foris Ventures, LLC [Member] | August Foris Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Face Amount

$ 19,000,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 19,000,000

Debt Instrument, Repayment Price, Percent of Face Amount

100.00%

Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.50%

Line of Credit Facility, Maximum Borrowing Capacity

$ 8,000,000

Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, Second Installment [Member]

Debt Instrument, Face Amount

$ 3,000,000

Line of Credit Facility, Incremental Draw Down Amount

$ 3,000,000

3,000,000

Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, Third Installment [Member]

Debt Instrument, Face Amount

$ 2,000,000

Extinguishment of Debt, Amount

1,500,000

Line of Credit Facility, Incremental Draw Down Amount

$ 2,000,000

2,000,000

Subsequent Event [Member] | DSM International B.V. [Member] | The 2019 DSM Credit Agreement, First Installment [Member]

Debt Instrument, Face Amount

3,000,000

Line of Credit Facility, Incremental Draw Down Amount

$ 3,000,000

Subsequent Event [Member] | The Investors [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 12,500,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues | shares

2,832,440

6,732,369

Shares Issued, Price Per Share | $ / shares

$ 5.12

$ 2.87

Proceeds from Issuance of Common Stock

$ 20,000,000

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement, April 26, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

3,983,230

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.12

$ 3.90

$ 3.90

Class of Warrant or Right, Term

2 years

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 4.56

$ 3.90

Class of Warrant or Right, Term

2 years

Debt Conversion, Converted Instrument, Warrants Issued | shares

352,638

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Private Placement, April 16, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

5,424,804

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 2.87

Class of Warrant or Right, Term

2 years

Subsequent Event [Member] | Foris Ventures, LLC [Member] | Rule 144A Convertible Notes [Member]

Debt Conversion, Original Debt, Amount

$ 5,000,000

Debt Conversion, Converted Instrument, Shares Issued | shares

1,122,460

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues | shares

1,243,781

323,382

2,043,781

Shares Issued, Price Per Share | $ / shares

$ 4.02

$ 4.02

$ 4.02

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement, April 26, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,635,025

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Warrants Issued for 2014 Rule 144A Convertible Notes Exchanges [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.02

Class of Warrant or Right, Term

2 years

2 years

Debt Conversion, Converted Instrument, Warrants Issued | shares

1,391,603

1,391,603

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement April 29, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

258,704

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Private Placement May 3, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

995,024

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 5.02

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | Other Non-affiliated Investors [Member] | Rule 144A Convertible Notes [Member]

Repayments of Debt

$ 37,900,000

Debt Conversion, Original Debt, Amount

$ 13,500,000

Debt Conversion, Converted Instrument, Shares Issued | shares

3,479,008

3,479,008

Subsequent Event [Member] | Vivo Capital LLC [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues | shares

913,529

Shares Issued, Price Per Share | $ / shares

$ 4.76

Subsequent Event [Member] | Vivo Capital LLC [Member] | Private Placement April 29, 2019 [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,212,787

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 4.76

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | DSM International B.V. [Member]

Consideration Transferred

57,000,000

Consideration Transferred, Cash Amount

29,100,000

Extinguishment of Debt, Amount

$ 27,900,000

Subsequent Event [Member] | Maxwell (Mauritius) Pte Ltd [Member] | Rule 144A Convertible Notes [Member]

Debt Conversion, Original Debt, Amount

$ 10,000,000

Debt Conversion, Converted Instrument, Shares Issued | shares

2,500,000

Subsequent Event [Member] | Total [Member] | Rule 144A Convertible Notes [Member]

Debt Instrument, Interest Rate, Stated Percentage

10.50%

Debt Conversion, Original Debt, Amount

$ 9,700,000

Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement [Member] | Aprinnova JV [Member]

First Priority Lien on Interests Owned by the Company

12.80%

Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement, First Installment [Member]

Proceeds from Issuance of Long-term Debt, Withheld as Prepayment of Interest Payable

$ 200,000

Subsequent Event [Member] | Nikko [Member] | Nikko Loan Agreement, Second Installment [Member]

Proceeds from Issuance of Long-term Debt, Withheld as Prepayment of Interest Payable

$ 100,000

Subsequent Event [Member] | The Cannabinoid Agreement [Member] | Lavvan [Member]

Agreement Amount

$ 300,000,000

Agreement, Amount of Research and Development Funding that Could Be Received

$ 300,000,000

Agreement, Profit Sharing to Be Received from the Counterparty, Period

20 years